Compare FNWB & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | PLRX |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 81.1M |
| IPO Year | 2012 | 2020 |
| Metric | FNWB | PLRX |
|---|---|---|
| Price | $10.19 | $1.27 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.50 | $2.67 |
| AVG Volume (30 Days) | 63.8K | ★ 571.1K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | ★ 36.00 | 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $1.09 |
| 52 Week High | $10.98 | $1.95 |
| Indicator | FNWB | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 46.43 |
| Support Level | $9.26 | $1.12 |
| Resistance Level | $10.33 | $1.36 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 84.96 | 50.00 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.